NVAX Q2 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$239M-42.4% YoY

Gross Profit

$225M94.1% margin

Operating Income

$106M44.2% margin

Net Income

$107M44.5% margin

EPS (Diluted)

$0.60

QoQ Revenue Growth

-64.1%

Cash Flow

Operating Cash Flow

-$127M

Free Cash Flow

-$128M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.3B

Stockholders' Equity

$38M

Cash & Equivalents

$254M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$239M	$415M	-42.4%
Gross Profit	$225M	$369M	-39.1%
Operating Income	$106M	$161M	-34.4%
Net Income	$107M	$162M	-34.4%

Revenue Segments

Supply Sales

$13M60%

Product

$11M50%

Nuvaxovid Sales

-$2M-10%

Geographic Segments

UNITED STATES

$198M83%

Rest of the World

$37M16%

Europe

$4M2%